Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc (PRTC) generates a steady flow of news as a hub-and-spoke biotherapeutics company advancing multiple clinical-stage programs through its own R&D engine and its Founded Entities. Company announcements frequently highlight clinical data, regulatory interactions, portfolio updates, and strategic developments tied to its capital-efficient model.
Recent news releases describe PureTech’s work in idiopathic pulmonary fibrosis via deupirfenidone (LYT-100), which is being advanced toward Phase 3 development by its Founded Entity Celea Therapeutics. Updates have included Phase 2b ELEVATE IPF trial results, open-label extension data, and sub-analyses in older patient populations, as well as regulatory meetings and planning for a pivotal Phase 3 trial. These stories provide insight into how PureTech and Celea are positioning deupirfenidone as a potential new standard of care in fibrotic lung disease.
News items also cover hematologic oncology through Gallop Oncology, another PureTech Founded Entity. Gallop has reported initial topline results from a Phase 1b trial of LYT-200 in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, including safety findings, response rates, and plans for a potentially registrational Phase 2 trial. Additional releases describe ongoing data presentations at major scientific meetings and continued maturation of survival data.
Beyond respiratory and oncology programs, PureTech’s news feed features updates from Seaport Therapeutics, such as the dosing of the first participant in a Phase 1 study of GlyphAgo (SPT-320) for generalized anxiety disorder, as well as corporate developments like leadership changes, half-year financial reports, and conference presentations including appearances at the J.P. Morgan Healthcare Conference. Investors and followers of PRTC can use this news page to track clinical milestones, strategic shifts, and the evolution of PureTech’s portfolio across its hub-and-spoke structure.
PureTech Health (Nasdaq: PRTC, LSE: PRTC) announces the retirement of Chief Operating Officer Stephen Muniz, effective May 17, 2021. Bharatt Chowrira, President and Chief of Business and Strategy, will take over Muniz's responsibilities. CEO Daphne Zohar praised Muniz's contributions during his 13-year tenure, emphasizing his role in building a strong operations and legal team. PureTech focuses on developing innovative therapies for severe diseases, with a pipeline of 24 therapeutics, including two with FDA clearance.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) will release its annual report and financial results on April 15, 2021, covering the fiscal year ending December 31, 2020. This report will detail the company's financial status, including cash balances for Q1 2021, and offer insights into its Wholly Owned Pipeline and Founded Entities as well as its environmental, social, and governance (ESG) practices. A conference call for analysts is scheduled for the same day at 9:00 AM EDT, with a live webcast available on the company's investor website.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced that Chief Financial Officer George Farmer, Ph.D., will present at the Barclays Global Healthcare Conference on March 10th at 10:20 AM EST. A webcast of the presentation will be available on the company's investor relations page. PureTech focuses on developing innovative medicines for critical diseases, boasting a pipeline of 24 products, including two that received FDA clearance and European marketing authorization. The company leverages unique insights into the brain, immune, and gut systems to drive its research and development efforts.
PureTech Health (NASDAQ: PRTC) notes the announcement from its Founded Entity, Karuna Therapeutics (NASDAQ: KRTX), regarding the pricing of its public offering. Karuna will offer 2,083,334 shares at $120.00 per share, aiming for gross proceeds of approximately $250 million. An additional 312,500 shares may be purchased by underwriters within 30 days. The offering is expected to close around March 4, 2021. Goldman Sachs and J.P. Morgan are the joint book-running managers for this offering.
Vedanta Biosciences, a pioneering clinical-stage microbiome company, announced participation in several virtual investor conferences. Key events include the Chardan 3rd Annual Microbiome Medicines Summit on March 8, 2021, at 2:00 PM ET; the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 AM ET; and the Credit Suisse 2021 Healthcare Innovators Series on March 11, 2021, at 12:20 PM ET. The company focuses on developing oral therapies for immune-mediated diseases using rationally defined bacterial consortia.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) has published a research paper in the Journal of Controlled Release demonstrating preclinical proof-of-concept for its Glyph platform technology. This platform enables targeted oral administration of therapeutics like mycophenolic acid directly to the lymphatic system, bypassing first-pass metabolism. The study showed an over 80-fold increase in lymphatic uptake and a more than 20-fold increase in concentrations in mesenteric lymph nodes. This innovative delivery method may enhance treatment for autoimmune diseases and cancers.
PureTech Health (Nasdaq: PRTC) acknowledges the publication of Karuna Therapeutics' EMERGENT-1 Phase 2 trial results for KarXT, aimed at treating schizophrenia, in the New England Journal of Medicine. The trial demonstrated a statistically significant 11.6-point reduction in PANSS total score compared to placebo at Week 5 (p0.0001). Incidences of side effects were similar in both treatment groups. KarXT is now advancing into Phase 3 development, providing a potential novel therapy for over 21 million people globally affected by schizophrenia.
PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) announces the participation of key executives in the SVB Leerink 10th Annual Global Healthcare Conference on February 26 at 10:00 AM EST. The panel will feature Bharatt Chowrira, George Farmer, and Michael Chen, who will discuss the company's ongoing efforts in developing innovative biotherapeutics for serious diseases. A live webcast of the event will be available for interested stakeholders.
PureTech Health (LSE: PRTC, Nasdaq: PRTC) announced that its Founded Entity, Vor Biopharma (Nasdaq: VOR), successfully closed its IPO, raising approximately $203.4 million by selling nearly 11.3 million shares at $18.00 per share. Following the offering, PureTech retains 3,207,200 shares of Vor, accounting for about 8.6% of Vor's outstanding shares. This capital aims to advance Vor’s engineered hematopoietic stem cell therapies for cancer treatment, bolstering PureTech’s broader pipeline of clinical-stage therapeutics.
PureTech Health (LSE: PRTC, Nasdaq: PRTC) has sold 1 million shares of Karuna Therapeutics (Nasdaq: KRTX) for approximately $118 million via a block trade executed by Morgan Stanley. The company plans to utilize the proceeds to enhance its clinical-stage pipeline. After the sale, PureTech holds about 9% of Karuna's outstanding shares, totaling 2,406,564 shares. The transaction was authorized by shareholders on August 26, 2020, and PureTech will update its financial guidance in its upcoming 2020 Annual Report.